STAT+: How AI helps drug developers skirt pharma's 'dirty little secret'

Andrew Pierce is the senior vice president of discovery and development at a company that claims to be “first end-to-end AI biotech,” but he admits he doesn’t know the first thing about artificial intelligence.

“For an older school person like me, it looks like magic, which is fine actually. I’m perfectly happy for the wizards to help me out in drug development and help speed medicines to […] the right patients,” he said.

Oncology researcher Pierce works at Owkin, a Paris-based biotech with a modest goal for AI, he says with a laugh: To double the chances of drug development success from the industry standard of around 10%, to 20%.

Continue to STAT+ to read the full story…